Squamous Cell Carcinoma - Pipeline Insight, 2024

Squamous Cell Carcinoma - Pipeline Insight, 2024

DelveInsight’s, “Squamous Cell Carcinoma - Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Squamous Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Squamous Cell Carcinoma: Understanding

Squamous Cell Carcinoma: Overview

Squamous cell carcinoma (SCC) is a type of skin cancer that arises from the squamous cells in the epidermis, the outermost layer of the skin. It is the second most common form of skin cancer, accounting for approximately 20% of all skin cancer cases. SCC is characterized by its aggressive behavior, with a high potential for metastasis and poor overall survival rates. The primary risk factor for developing SCC is cumulative exposure to ultraviolet (UV) radiation, particularly in childhood and youth. Additionally, immunosuppression, chronic inflammation, and genetic mutations, such as those in the p53 gene, also contribute to the development of SCC.

Squamous cell carcinoma (SCC) is a type of cancer that can occur in various parts of the body, including the skin, lungs, head and neck, esophagus, urinary tract, prostate, vagina, and cervix. The most common types of SCC are non-melanoma skin cancer, head and neck cancer, esophageal cancer, and non-small cell lung cancer. SCCs share many phenotypic and molecular characteristics, and numerous genetic alterations have been described in these subtypes. The molecular mechanisms contributing to tumor initiation and progression are still poorly understood, but advances in diagnostic methods and combined treatment modalities are essential for improving survival rates. SCCs are often classified based on their anatomical site of origin, such as cutaneous SCC (cSCC), which develops in the skin, and oral SCC, which makes up most mouth cancers. Lung SCC is another significant type, accounting for about 90% of all lung cancers.

The most common symptoms include the appearance of rough, reddish, scaly areas on the skin, often with raised borders. These patches can also be open sores or have a brown spot resembling an age spot. In some cases, SCC can manifest as a firm, dome-shaped growth, a wart-like growth, or even a tiny, horn-like growth. The cancer can also develop in areas of the body that are not typically exposed to the sun, such as the palms, soles, or genital areas. Additionally, SCC can cause symptoms like itching, soreness, or numbness in the affected area.

The treatment and management of squamous cell carcinoma (SCC) in the lungs, head, and neck involve a multidisciplinary approach tailored to the specific characteristics of the cancer. For squamous cell carcinoma of the lungs, treatment typically involves surgery followed by chemotherapy, with lobectomy preferred for stage II tumors. In cases where surgery is not feasible, sub-lobar resection may be considered. Additionally, chemotherapy options are available for patients with metastatic or recurrent SCC of the head and neck. In the case of head and neck SCC, treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy, either individually or in combination, depending on the stage and location of the cancer. Preservation of function and quality of life are crucial considerations in treatment planning, with a focus on minimizing side effects and maximizing outcomes. Close monitoring and follow-up are essential components of managing SCC to ensure optimal results and address any potential complications promptly.

""Squamous Cell Carcinoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Squamous Cell Carcinoma pipeline landscape is provided which includes the disease overview and Squamous Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Squamous Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Squamous Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Squamous Cell Carcinoma.

Squamous Cell Carcinoma Emerging Drugs Chapters

This segment of the Squamous Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Squamous Cell Carcinoma Emerging Drugs

NBTXR-3: Nanobiotix

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.

mRNA-4157: Moderna Therapeutics

mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck’s anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.

HB-200: Hookipa Pharma

HB-200 is HOOKIPA’s lead oncology candidate engineered with the company’s proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.

MCLA-158: Merus

MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.

HFB-301001: HiFiBiO

HFB301001 is a novel fully human IgG1 class OX-40 agonistic antibody with an optimized pharmacological profile. In contrast to other anti-OX-40 antibodies, the agonistic activity of HFB301001 is further enhanced in the presence of the endogenous ligand OX-40L and does not result in reduced expression of OX-40 on T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with squamous cell carcinoma.

Further product details are provided in the report……..

Squamous Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Squamous Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

MajorPlayers in Squamous Cell Carcinoma

There are approx. 75+ key companies which are developing the therapies for Squamous Cell Carcinoma. The companies which have their Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, Nanobiotix.

Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Squamous Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Squamous Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Squamous Cell Carcinoma drugs.

Squamous Cell Carcinoma Report Insights

Squamous Cell Carcinoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Squamous Cell Carcinoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Squamous Cell Carcinoma drugs?

How many Squamous Cell Carcinoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Squamous Cell Carcinoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Squamous Cell Carcinoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Squamous Cell Carcinoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Hookipa Pharma

Zenith Epigenetics

HiFiBiO

Nanobiotix

GSK

AstraZeneca

VCN Biosciences

Moderna Therapeutics

Exelixis

MacroGenics

Nykode Therapeutics

Tizona Therapeutics

Totus Medicines

Turnstone Biologics

Hoffmann-La Roche

Merus

Key Products

HB-200

ZEN003694

HFB-301001

NBTXR-3

GSK-4057190

Olaparib

VCN-01

mRNA-4157

XL092

Vobramitamab duocarmazine

VB10.NEO

TTX-080

TOS-358

TBio-4101

RG6058

MCLA-158

Please Note: It will take 7-8 business days to complete the report upon order confirmation.